Chemerin Levels in COVID-19 Are More Affected by Underlying Diseases than by the Virus Infection Itself

Chemerin Levels in COVID-19 Are More Affected by Underlying Diseases than by the Virus Infection Itself

Blog Article

Background/Objectives: Chemerin is an adipokine involved in inflammatory and metabolic diseases, and its circulating levels have been associated with inflammatory parameters in various patient cohorts.Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, which causes COVID-19, triggers inflammatory pathways.However, the association between serum chemerin levels and COVID-19 disease severity Christmas Tree and outcomes has not been definitively established.Methods: In this study, serum chemerin levels were analyzed in 64 patients with moderate COVID-19 and 60 patients with severe disease.Results: The results showed that serum chemerin levels were comparable between these two groups and slightly higher than in healthy controls.

Notably, COVID-19 patients with hypertension exhibited elevated serum chemerin levels, while those with liver cirrhosis had lower levels.When patients with these comorbidities were excluded from the analyses, serum chemerin levels in COVID-19 patients were similar to those in healthy controls.Positive correlations were observed between serum chemerin levels and markers such as alkaline phosphatase, C-reactive protein, eosinophils, and lymphocytes in the entire cohort, as well as in the subgroup excluding patients with hypertension and cirrhosis.Additionally, urinary chemerin levels were Wooden Keychain comparable between COVID-19 patients and controls, and neither hypertension nor dialysis significantly affected urinary chemerin levels.Both survivors and non-survivors had similar serum and urinary chemerin levels.

Conclusions: In conclusion, this study suggests that comorbidities such as arterial hypertension and liver cirrhosis do have a more significant impact on serum chemerin levels than SARS-CoV-2 infection itself.